|
1
|
Young RJ, Brown NJ, Reed MW, Hughes D and
Woll PJ: Angiosarcoma. Lancet Oncol. 11:983–991. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khalid K, Khan A, Lomiguen CM and Chin J:
Clinical detection of primary pulmonary angiosarcoma. Cureus.
13:e170592021.PubMed/NCBI
|
|
3
|
Rana MK, Rahman O and O'Brien A: Primary
pulmonary angiosarcoma. BMJ Case Rep. 14:e2445782021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ren Y, Zhu M, Liu Y, Diao X and Zhang Y:
Primary pulmonary angiosarcoma: Three case reports and literature
review. Thorac Cancer. 7:607–613. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luan T, Hao J, Gu Y, He P, Li Y, Wang L,
Deng H, Guan W, Lin X, Xie X, et al: A clinical analysis and
literature review of eleven cases with primary pulmonary
angiosarcoma. BMC Cancer. 24:15972024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Huang X, Peng C, Wang Y, Wu Q, Wu
Z, Shao H and Wang W: Primary pulmonary epithelioid angiosarcoma: A
case report and literature review. J Cancer Res Ther. 14
(Suppl):S533–S535. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tang X, Zhu J, Zhu F, Tu H, Deng A, Lu J,
Yang M, Dai L, Huang K and Zhang L: Case report: Primary pulmonary
angiosarcoma with brain metastasis. Front Bioeng Biotechnol.
9:8038682021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Basiri R, Ziaei Moghaddam A, Rikhtegar A
and Jafarian AH: Primary pulmonary angiosarcoma found incidentally
in a complicated patient: A rare case report. Clin Respir J.
18:e138182024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Y, Ma X, Chen J, Wang H and Yu Z:
Nontuberculous mycobacteria by metagenomic next-generation
sequencing: Three cases reports and literature review. Front Public
Health. 10:9722802022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gu W, Miller S and Chiu CY: Clinical
metagenomic next-generation sequencing for pathogen detection. Annu
Rev Pathol. 14:319–338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bejaoui S, Nielsen SH, Rasmussen A, Coia
JE, Andersen DT, Pedersen TB, Møller MV, Kusk Nielsen MT, Frees D
and Persson S: Comparison of Illumina and Oxford Nanopore
sequencing data quality for Clostridioides difficile genome
analysis and their application for epidemiological surveillance.
BMC Genomics. 26:922025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A MapReduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang B, Fang WT and Zhong H: Introduction
to the 9th edition of TNM classification for lung
cancer. Zhonghua Zhong Liu Za Zhi. 46:206–210. 2024.(In Chinese).
PubMed/NCBI
|
|
14
|
Bonito FJP, de Almeida Cerejeira D,
Dahlstedt-Ferreira C, Oliveira Coelho H and Rosas R:
Radiation-induced angiosarcoma of the breast: A review. Breast J.
26:458–463. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Piechuta A, Przybyłowski T, Szołkowska M
and Krenke R: Hemoptysis in a patient with multifocal primary
pulmonary angiosarcoma. Pneumonol Alergol Pol. 84:283–289.
2016.PubMed/NCBI
|
|
16
|
Lim R, Harper L and Swiston J: Clinical
manifestations and diagnostic methods in pulmonary angiosarcoma:
Protocol for a scoping review. Syst Rev. 6:1362017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu M, Huang W, Wang Y, Wang G, Wang L, Tao
W, Faiz SA, Ng FH and Li H: Pulmonary angiosarcoma presenting with
diffuse alveolar hemorrhage: A case report. Ann Transl Med.
9:742021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Studer LL and Selby DM: Hepatic
Epithelioid Hemangioendothelioma. Arch Pathol Lab Med. 142:263–267.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Giuffrida MA, Bacon NJ and Kamstock DA:
Use of routine histopathology and factor VIII-related antigen/von
Willebrand factor immunohistochemistry to differentiate primary
hemangiosarcoma of bone from telangiectatic osteosarcoma in 54
dogs. Vet Comp Oncol. 15:1232–1239. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Silwal A, B R S, Rehman S, Daing A,
Gopagoni R, Alyas Akram M, Saeed A, Sadiq KO, Farrukh AM and
Harikrishna A: Bladder angiosarcoma: A systematic literature review
and survival analysis. Proc (Bayl Univ Med Cent). 38:305–312.
2025.PubMed/NCBI
|
|
21
|
Kapagan T, Bulut N, Erdem GU, Yıldırım S,
Erdem ZB and Sahin H: Synchronous double Primary Angiosarcoma
originating from the stomach and rectum: A case report and a
literature review. Arch Iran Med. 27:168–173. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Salehi M, Rehman S, Davis S and Jafari HR:
Angiosarcoma of gallbladder, a literature review. J Med Case Rep.
18:622024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma XM, Yang BS, Yang Y, Wu GZ, Li YW, Yu
X, Ma XL, Wang YP, Hou XD and Guo QH: Small intestinal angiosarcoma
on clinical presentation, diagnosis, management and prognosis: A
case report and review of the literature. World J Gastroenterol.
29:561–578. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Palassini E, Baldi GG, Sulfaro S,
Barisella M, Bianchi G, Campanacci D, Fiore M, Gambarotti M,
Gennaro M, Morosi C, et al: Clinical recommendations for treatment
of localized angiosarcoma: A consensus paper by the Italian Sarcoma
Group. Cancer Treat Rev. 126:1027222024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fujimura T, Maekawa T, Kato H, Ito T,
Matsushita S, Yoshino K, Fujisawa Y, Ishizuki S, Segawa K, Yamamoto
J, et al: Treatment for taxane-resistant cutaneous angiosarcoma: A
multicenter study of 50 Japanese cases. J Dermatol. 50:912–916.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou
C, Smith KD, Phung TL, Pollock RE, Benjamin R, Hunt KK, et al:
Angiosarcoma: Clinical and molecular insights. Ann Surg.
251:1098–1106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bartakke AA and Saez de Ibarra Sanchez JI:
Successful perioperative management of a primary pulmonary arterial
angiosarcoma: Case report. Braz J Anesthesiol.
74:7441862024.PubMed/NCBI
|
|
28
|
Cao J, Wang J, He C and Fang M:
Angiosarcoma: A review of diagnosis and current treatment. Am J
Cancer Res. 9:2303–2313. 2019.PubMed/NCBI
|
|
29
|
Ito T, Uchi H, Nakahara T, Tsuji G, Oda Y,
Hagihara A and Furue M: Cutaneous angiosarcoma of the head and
face: A single-center analysis of treatment outcomes in 43 patients
in Japan. J Cancer Res Clin Oncol. 142:1387–1394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Noguchi G, Ota J, Ishigaki H, Onuki T,
Kato Y and Moriyama M: A case of retroperitoneal angiosarcoma
effectively treated with recombinant interleukin-2. Nihon Hinyokika
Gakkai Zasshi. 103:697–703. 2012.(In Japanese). PubMed/NCBI
|
|
31
|
Park MS, Ravi V and Araujo DM: Inhibiting
the VEGF-VEGFR pathway in angiosarcoma, epithelioid
hemangioendothelioma, and hemangiopericytoma/solitary fibrous
tumor. Curr Opin Oncol. 22:351–355. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jones RL, Ravi V, Brohl AS, Chawla S,
Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD,
et al: Efficacy and safety of TRC105 Plus Pazopanib vs Pazopanib
alone for treatment of patients with advanced angiosarcoma: A
randomized clinical trial. JAMA Oncol. 8:740–747. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Edemskiy A, Vasiltseva O, Kliver E,
Novikova N, Sirota D and Chernyavskiy A: Surgical treatment of
pulmonary artery Angiosarcoma-a ten-year experience. Braz J
Cardiovasc Surg. 40:e202304412025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin Y, Yu H, Wang C and Zhang D: Primary
pulmonary angiosarcoma mimicking diffuse pulmonary hemorrhage: A
case report. Oncol Lett. 25:2112023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu L, Sun Y, Wang M, Yuan L, Wang Q and
Qian X: Primary pulmonary epithelioid angiosarcoma with thyroid
tumor history: A case report and literature review. Exp Ther Med.
24:4712022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Painter CA, Jain E, Tomson BN, Dunphy M,
Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Gómez Tejeda
Zañudo J, et al: The angiosarcoma project: Enabling genomic and
clinical discoveries in a rare cancer through patient-partnered
research. Nat Med. 26:181–187. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vargas AC, Maclean FM, Sioson L, Tran D,
Bonar F, Mahar A, Cheah AL, Russell P, Grimison P, Richardson L and
Gill AJ: Prevalence of PD-L1 expression in matched recurrent and/or
metastatic sarcoma samples and in a range of selected sarcomas
subtypes. PLoS One. 15:e02225512020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jin J, Xie Y, Zhang JS, Wang JQ, Dai SJ,
He WF, Li SY, Ashby CR Jr, Chen ZS and He Q: Sunitinib resistance
in renal cell carcinoma: From molecular mechanisms to predictive
biomarkers. Drug Resist Updat. 67:1009292023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee AQ, Hao C, Pan M, Ganjoo KN and Bui
NQ: Histologic and immunologic factors associated with response to
immune checkpoint inhibitors in advanced sarcoma. Clin Cancer Res.
31:678–684. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Googe PB, Flores K, Jenkins F, Merritt B,
Moschos SJ and Grilley-Olson JE: Immune Checkpoint markers in
superficial angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and
tumor-infiltrating lymphocytes. Am J Dermatopathol. 43:556–559.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kösemehmetoğlu K, Özoğul E, Babaoğlu B,
Tezel GG and Gedikoğlu G: Programmed death Ligand 1 (PD-L1)
expression in malignant mesenchymal tumors. Turk Patoloji Derg.
1:192–197. 2017.PubMed/NCBI
|
|
42
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu
K: Combination strategies with PD-1/PD-L1 blockade: Current
advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Whitlock RS, Ebare K, Cheng LS, Fishman
DS, Mills JL, Nguyen HN, Nuchtern JG, Ruan W, Smith VE, Patel KA,
et al: Angiosarcoma of the pancreas in a pediatric patient with an
activating KDR-internal tandem duplication: A case report and
review of the literature. J Pediatr Hematol Oncol. 44:e751–e755.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Odintsov I, Papke DJ, George S, Padera RF,
Hornick JL and Siegmund SE: Genomic profiling of cardiac
angiosarcoma reveals novel targetable KDR variants, recurrent MED12
mutations, and a high burden of Germline POT1 alterations. Clin
Cancer Res. 31:1091–1102. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Omiyale AO: Primary vascular tumours of
the kidney. World J Clin Oncol. 12:1157–1168. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Beca F, Krings G, Chen YY, Hosfield EM,
Vohra P, Sibley RK, Troxell ML, West RB, Allison KH and Bean GR:
Primary mammary angiosarcomas harbor frequent mutations in KDR and
PIK3CA and show evidence of distinct pathogenesis. Mod Pathol.
33:1518–1526. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Torrence D and Antonescu CR: The genetics
of vascular tumours: An update. Histopathology. 80:19–32. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nilsson MB, Giri U, Gudikote J, Tang X, Lu
W, Tran H, Fan Y, Koo A, Diao L, Tong P, et al: KDR amplification
is associated with VEGF-induced activation of the mTOR and invasion
pathways but does not predict clinical benefit to the VEGFR TKI
Vandetanib. Clin Cancer Res. 22:1940–1950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Styring E, Seinen J, Dominguez-Valentin M,
Domanski HA, Jönsson M, von Steyern FV, Hoekstra HJ, Suurmeijer AJ
and Nilbert M: Key roles for MYC, KIT and RET signaling in
secondary angiosarcomas. Br J Cancer. 111:407–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang L, Liu L, Han B, Han W and Zhao M:
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: A case
report. BMC Cancer. 18:6182018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dickerson EB, Marley K, Edris W, Tyner JW,
Schalk V, Macdonald V, Loriaux M, Druker BJ and Helfand SC:
Imatinib and dasatinib inhibit hemangiosarcoma and implicate
PDGFR-β and Src in tumor growth. Transl Oncol. 6:158–168. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Homsi J and Daud AI: Spectrum of activity
and mechanism of action of VEGF/PDGF inhibitors. Cancer Control.
14:285–294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Terada T: Angiosarcoma of the oral cavity.
Head Neck Pathol. 5:67–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Prenen H, Smeets D, Mazzone M, Lambrechts
D, Sagaert X, Sciot R and Debiec-Rychter M: Phospholipase C gamma 1
(PLCG1) R707Q mutation is counterselected under targeted therapy in
a patient with hepatic angiosarcoma. Oncotarget. 6:36418–34425.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu L, Xie X, Shi X, Zhang P, Liu A, Wang J
and Zhang B: Potential application of genomic profiling for the
diagnosis and treatment of patients with sarcoma. Oncol Lett.
21:3532021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Disel U, Madison R, Abhishek K, Chung JH,
Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V,
Karadurmus N, et al: The Pan-cancer landscape of coamplification of
the tyrosine kinases KIT, KDR, and PDGFRA. Oncologist. 25:e39–e47.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mir O, Cropet C, Toulmonde M, Cesne AL,
Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A,
et al: Pazopanib plus best supportive care versus best supportive
care alone in advanced gastrointestinal stromal tumours resistant
to imatinib and sunitinib (PAZOGIST): A randomised, multicentre,
open-label phase 2 trial. Lancet Oncol. 17:632–641. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Demlová R, Turjap M, Peš O, Kostolanská K
and Juřica J: Therapeutic drug monitoring of sunitinib in
gastrointestinal stromal tumors and metastatic renal cell carcinoma
in adults-a review. Ther Drug Monit. 42:20–32. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Dufies M, Giuliano S, Viotti J,
Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola
J, Claren A, et al: CXCL7 is a predictive marker of sunitinib
efficacy in clear cell renal cell carcinomas. Br J Cancer.
117:947–953. 2017. View Article : Google Scholar : PubMed/NCBI
|
